張志濱?傅春戀?郭軼

[摘要] 目的 探析維持性精神分裂癥在奧氮平治療下的臨床效果。 方法 選取2015年1月～2016年1月于我院接受治療的60例維持性精神分裂癥的患者，所有患者按照隨機(jī)數(shù)字表法均分為兩組（對(duì)照組與觀察組），其中對(duì)照組予以氯氮平治療，觀察組予以?shī)W氮平治療，比較兩組患者在不同治療方法下的臨床效果（治療前后的精神癥狀評(píng)分、PANSS評(píng)分（陽(yáng)性與陰性癥狀量表評(píng)分）、不良反應(yīng)發(fā)生情況）。 結(jié)果 兩組患者治療后的精神癥狀評(píng)分均較治療前低，且其差異具有統(tǒng)計(jì)學(xué)意義（P<0.05），但是兩組治療后的組間差異不存在統(tǒng)計(jì)學(xué)意義（P>0.05）；兩組患者治療后的PANSS評(píng)分亦較治療前低，且其差異具有統(tǒng)計(jì)學(xué)意義（P<0.05），但是兩組治療后的組間差異不存在統(tǒng)計(jì)學(xué)意義（P>0.05）；對(duì)照組的不良反應(yīng)發(fā)生率（33.33%）較觀察組（10.00%）高，且其差異具有統(tǒng)計(jì)學(xué)意義（P<0.05）。 結(jié)論 對(duì)維持性精神分裂癥患者而言，予用奧氮平進(jìn)行治療不僅具有較佳的臨床效果，且具有可觀的安全性，因而值得推廣應(yīng)用。

[關(guān)鍵詞] 維持性精神分裂癥；奧氮平；治療效果；PANSS評(píng)分

[中圖分類號(hào)] R479.3 [文獻(xiàn)標(biāo)識(shí)碼] A [文章編號(hào)] 2095-0616（2017）16-32-03

Clinical effect of olanzapine in treatment of maintaining schizophrenia

ZHANG Zhibin FU Chunlian GUO Yi

Guangzhou Civil Affairs Bureau Mental Hospital，Guangzhou 510430，China

[Abstract] Objective To explore and analyze clinical effect of olanzapine in treatment of maintaining schizophrenia. Methods 60 patients with maintaining schizophrenia who were treated in our hospital from January 2015 to January 2016 were analyzed. According to random number table，they were divided into two groups （the control group and the observation group）.The control group was given clozapine while the observation group was given olanzapine.Clinical effects of different methods （psychiatric symptom scores before and after treatment），PANSS score （Positive and Negative Syndrome Scale） and adverse reactions of patients in two groups were compared and analyzed. Results Psychiatric symptom scores after treatment of patients in two groups were all lower than those before treatment.The difference was statistically significant（P<0.05）.After treatment，difference between two groups had no statistical significance （P>0.05）.PANSS score after treatment of patients in two groups was also lower than that before treatment.The difference was statistically significant（P<0.05）.After treatment，difference between two groups had no statistical significance（P>0.05）.Rate of adverse reactions in the control group was 33.33%，higher than that in the observation group（10.00%）.The difference was statistically significant（P<0.05）. Conclusion Olanzapine in treatment of patients with maintaining schizophrenia not only has better clinical effect，but also has good safety，which is worthy of promotion and application.

[Key words] Maintaining schizophrenia；Olanzapine；Treatment effect；PANSS score

精神分裂癥是一種基于個(gè)性、情感、思維、行為等分裂的精神科疾病，具有慢性發(fā)展、反復(fù)發(fā)作等特點(diǎn)，多發(fā)于青壯年人群[1]。精神分裂癥的主要征兆被認(rèn)為是基本的思考結(jié)構(gòu)與認(rèn)知能力發(fā)生破裂，因而極大程度上會(huì)出現(xiàn)精神活動(dòng)與環(huán)境不協(xié)調(diào)的行為，進(jìn)而可能會(huì)對(duì)社會(huì)與家庭帶來(lái)較為嚴(yán)重的影響；由此可見(jiàn)，對(duì)該類病癥患者進(jìn)行早期、積極地治療及干預(yù)尤為重要且迫切[2]。但是基于對(duì)治療安全性與高效性的考慮，臨床上應(yīng)盡量選用便于長(zhǎng)期使用、作用性廣泛、不良反應(yīng)作用性低的藥物[3]。奧氮平是我國(guó)目前針對(duì)抗精神病的新型藥物之一，其臨床的作用性與安全性一直得到認(rèn)可，因而具有進(jìn)一步展開(kāi)探究的價(jià)值，因此本研究旨在前人的研究基礎(chǔ)上進(jìn)一步分析這一藥物在維持性精神分裂癥治療中的作用性，現(xiàn)報(bào)道如下。endprint